Hormone receptors over the last 8 years in a cancer referral center in India: What was and what is?

Indian Journal of Pathology and Microbiology

Volumn 52, Issue 2, 2009, Pages 171-174

  Shet, Tanuja ^a   Agrawal, Atin ^a   Nadkarni, Mandar ^a   Palkar, Mahendra ^a   Havaldar, Rohini ^a   Parmar, Vani ^a   Badwe, Rajendra ^a   Chinoy, R F ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Breast cancer; Estrogen receptors; Immunohistochemical method; Progesterone receptors

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CENTER; CANCER PATIENT; CANCER STAGING; ESTROGEN BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; INCIDENCE; INDIA; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PROGESTERONE BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR CLASSIFICATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HOSPITALS; HUMANS; INCIDENCE; INDIA; MALE; MIDDLE AGED; NEOPLASM STAGING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 63449118326     PISSN: 03774929     EISSN: None     Source Type: Journal    
DOI: 10.4103/0377-4929.48909     Document Type: Article

References (24)

1. Zafrani B, Aubriot MH, Mouret E, De Cremoux P, De Rycke Y, Nicolas A, et al. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: Comparisonwith biochemical determination in a prospective study of 793 cases. Histopathology 2000;37:536-45.
2. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
3. Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routinepractice: Interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125-30.
4. Barnes DM, Millis RR, Beex LV, Thorpe SM, Leake RE. Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: The need for quality assurance. Eur J Cancer 1998;34:1677-82.
5. Layfield LJ, Gupta D, Mooney EE. Assessment of tissue estrogen and progesterone receptor levels: A survey of current practice, techniques, and quantitation methods. Breast J 2000;6:189-96.
6. Desai SB, Moonim MT, Gill AK, Punia RS, Naresh KN, Chinoy RF. Hormone receptor status of breast cancer in India: A study of 798 tumors. Breast 2000;9:267-70.
7. EBCTCG; Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: An overview of randomized trials. Lancet 1998;351:1451-67.
8. Elledge RM, Osborne CK. Estrogen receptors and breast cancer: It is time for individual treatment based on estrogen receptor status. BMJ 1997;314:1843-44.
9. Regitnig P, Reiner A, Dinges HP, Hofler G, Muller-Holzner E, Lax SF, et al. Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch 2002;441:328-34.
10. Wells CA, Sloane JP, Coleman D, Munt C, Amendoeira I, Apostolikas N, et al. Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union: An inter-laboratory study. Virchows Arch 2004;445:119-28.
11. Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 2002;11:601-7.
12. Redkar AA, Kabre SS, Mittra I. Estrogen and progesterone receptors measurement in breast cancer with enzyme-immunoassay and correlation with other prognostic factors. Indian J Med Res 1992;96:1-8.
13. Navani S, Bhaduri AS. High incidence of oestrogen receptor negative progesterone receptor positive phenotype in Indian breast cancer: Fact or fiction? Indian J Pathol Microbiol 2005;48:199-201.
14. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: Correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 2000;53:688-96.
15. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Anderson E, Bobrow LG, et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol 2001;115:44-58.
16. Pileri SA, Roncador G, Ceccarelli C, Piccioli M, Briskomatis A, Sabattini E, et al. Antigen retrieval techniques in immunohistochemistry: Comparison of different methods. J Pathol 1997;183:116-23.
17. Rhodes A, Jasani B, Balaton AJ, Miller KD. Immunohistochemical demonstration of oestrogen and progesterone receptors: Correlation of standards achieved on in house tumors with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 2000;53:292-301.
18. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr, Deshler A, et al. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 2000. J Natl Cancer Inst 2001;93:979-89.
19. Fisher ER, Anderson S, Dean S, Dabbs D, Fisher B, Siderits R, et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer 2005;103:164-73.
20. Olivotto IA, Truong PT, Speers CH, Bernstein V, Allan SJ, Kelly SJ, et al. Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol 2004; 22:1769-70.
21. Colomer R, Beltran M, Dorcas J, Cortes-Funes H, Hornedo J, Valentin V, et al. It is not time to stop progesterone receptor testing in breast cancer. J Clin Oncol 2005;23:3868-9.
22. Colozza M, Larsimont D, Piccart MJ. Progesterone receptor testing: Not the right time to be buried. J Clin Oncol 2005;23:3867-8.
23. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-9.
24. Bernoux A, de Cremoux P, Laine-Bidron C, Martin EC, Asselain B, Magdelenat H. Estrogen receptor negative and progesterone receptor positive primary breast cancer: Pathological characteristics and clinical outcome. Breast Cancer Res Treat 1998;49:219-25.